Graphite Bio

279 E Grand Ave, Suite 430
South San Francisco
CA
94063
United States

Show jobs for this employer

About Graphite Bio

Graphite Bio is driven to apply its breakthrough technology with urgency to advance therapies and cures for people living with serious diseases. 
 
Graphite Bio is a next-generation gene editing company focused on the development of potentially curative therapies for patients suffering from serious diseases. The company's targeted gene integration platform harnesses the natural cellular process of homology directed repair (HDR) to efficiently repair genetic defects at their source, deliver genetic cargo with precision and engineer new cellular effector functions. Graphite Bio is leveraging its differentiated platform, initially focused on ex vivo engineering of hematopoietic stem cells, to advance a portfolio of transformative treatments with potential for saving and dramatically improving patients' lives. The company was co-founded by academic pioneers in the fields of gene editing and gene therapy, including Maria Grazia Roncarolo, MD, and Matthew Porteus, MD, PhD, and is backed by Versant Ventures and Samsara BioCapital. 
 
More information is available at www.GraphiteBio.com. 

Graphite Bio corporate overview presentation from CEO Dr. Josh Lehrer at the 39th Annual J.P. Morgan Healthcare Conference

10 articles with Graphite Bio